PriceTargets.com logo

Addex Therapeutics - ADXN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$22.79 As of 04/16/2024 02:04 PM ET
▼ -1.96 (-7.92%)

This chart shows the closing price for ADXN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Addex Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADXN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADXN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Addex Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $22.79.

This chart shows the closing price for ADXN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Addex Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/25/2023HC WainwrightReiterated RatingNeutralLow
6/23/2022HC WainwrightDowngradeBuy ➝ NeutralLow
5/31/2022HC WainwrightLower TargetBuy$420.00 ➝ $300.00Low
2/11/2022HC WainwrightLower TargetBuy$560.00 ➝ $420.00Low
8/9/2021HC WainwrightReiterated RatingBuy$560.00High
6/29/2021HC WainwrightReiterated RatingBuy$560.00Medium
4/27/2021HC WainwrightInitiated CoverageBuy$560.00N/A
4/21/2021HC WainwrightInitiated CoverageBuy$560.00N/A
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/17/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/17/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Addex Therapeutics logo
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Read More

Today's Range

Now: $22.79
Low: $20.75
High: $22.90

50 Day Range

MA: $13.01
Low: $8.96
High: $27.90

52 Week Range

Now: $22.79
Low: $5.00
High: $27.90

Volume

18,923 shs

Average Volume

17,066 shs

Market Capitalization

$24.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Addex Therapeutics?

The following Wall Street analysts have issued stock ratings on Addex Therapeutics in the last twelve months: HC Wainwright.
View the latest analyst ratings for ADXN.

What is the current price target for Addex Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Addex Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Addex Therapeutics in the next year.
View the latest price targets for ADXN.

What is the current consensus analyst rating for Addex Therapeutics?

Addex Therapeutics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ADXN, but not buy more shares or sell existing shares.
View the latest ratings for ADXN.

What other companies compete with Addex Therapeutics?

Other companies that are similar to Addex Therapeutics include Sensei Biotherapeutics, Alaunos Therapeutics, Iterum Therapeutics, DURECT and Aileron Therapeutics. Learn More about companies similar to Addex Therapeutics.

How do I contact Addex Therapeutics' investor relations team?

Addex Therapeutics' physical mailing address is CHEMIN DES AULX 12 PLAN-LES-OUATES, GENEVA V8, CH-1228. The company's listed phone number is 011-41-22-884-1555 and its investor relations email address is [email protected]. The official website for Addex Therapeutics is www.addextherapeutics.com. Learn More about contacing Addex Therapeutics investor relations.